



Maelor plc

30th March 2004

MAELOR SIGNS MICELLE TECHNOLOGY AGREEMENT

Wrexham, UK: Maelor plc, the specialist healthcare products company, is pleased to announce that it has signed a collaborative study agreement with a US-based pharmaceutical company. Under the terms of this agreement Maelor will conduct micelle formulation work on a New Chemical Entity (NCE) currently in pre-clinical development.

This is the first agreement with an external party to apply Maelor's innovative micelle platform technology to an NCE. This early-stage collaborative work will have little revenue impact in the short term, but if successful the parties will discuss the future development and commercialisation of the product.

Stephen Appelbee, Maelor Chief Executive, said:

'This confirms Maelor's pre-eminent position in this field, and we look forward to the success of this project and possible future collaborations.'

Further information:

Maelor plc

Stephen Appelbee, Chief Executive Office 01978 810 153

Financial Dynamics

Ben Atwell/Lucy Briggs 020 7831 3113

Notes to Editors:

A micelle is an aggregation of polymers which attract one another to form an organised structure. These polymers are 'amphiphilic' i.e. they have a hydrophilic (water seeking) pole and a hydrophobic (water repelling) pole within the same chain. The hydrophobic poles attract each other, thus forming the interior of the micelle. This interior environment can carry lipophilic (fat loving) substances, while the hydrophilic poles can allow the micelles to disperse in water. In this way, a micelle can be used to 'solubilise' materials which have little or no solubility in water.